Incidentally, CYP2W1 is important for the activation and response to chemotherapy, such as mitotane in cancer [56], whereas high expression of CYP1B1 is known to drive gemcitabine resistance in pancreatic cancer [50]. This evidence concerns the gene CYP2W1 and pancreatic neoplasm.